Oculis Holding AG (OCS)
NASDAQ: OCS · Real-Time Price · USD
13.14
0.00 (0.00%)
Aug 18, 2026, 9:58 AM EDT - Market open
Oculis Holding AG Employees
Oculis Holding AG had 60 employees as of December 31, 2025. The number of employees increased by 11 or 22.45% compared to the previous year.
Employees
60
Change (1Y)
11
Growth (1Y)
22.45%
Revenue / Employee
$24,196
Profits / Employee
-$1,633,457
Market Cap
811.16M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 60 | 11 | 22.45% |
| Dec 31, 2024 | 49 | 13 | 36.11% |
| Dec 31, 2023 | 36 | 8 | 28.57% |
| Dec 31, 2022 | 28 | - | - |
| Sep 30, 2022 | 32 | - | - |
| Jun 30, 2022 | 32 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Pharming Group | 407 |
| Rigel Pharmaceuticals | 174 |
| DBV Technologies | 170 |
| Aura Biosciences | 113 |
| Silence Therapeutics | 88 |
| SpyGlass Pharma | 76 |
| Aclaris Therapeutics | 73 |
| Bright Minds Biosciences | 26 |
OCS News
- 3 days ago - Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - GlobeNewsWire
- 8 days ago - Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis' Position as an Emerging Leading Neuro-Ophthalmology Company - GlobeNewsWire
- 11 days ago - Oculis Reports Q2 2026 Financial Results and Provides Company Update - GlobeNewsWire
- 11 days ago - Oculis Holding AG Earnings release: Q2 2026 - Filings
- 15 days ago - Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses - GlobeNewsWire
- 6 weeks ago - Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference - GlobeNewsWire
- 2 months ago - Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026 - GlobeNewsWire
- 2 months ago - Oculis Holding AG Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts